Merck: efficacy endpoint achieved in RSV
(CercleFinance.com) - Merck announced on Tuesday that clesrovimab, its investigational treatment for bronchiolitis in infants, had met its endpoints in a Phase 2b/3 clinical trial.
This monoclonal antibody administered against the respiratory syncytial virus (RSV) met its efficacy and safety endpoints, notably reducing virus-related lower respiratory tract infections (LRTIs) after 150 days.
Merck - which says it is encouraged by these results - states that it plans to present detailed data from the study at a forthcoming scientific congress, before filing registration applications with health authorities worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This monoclonal antibody administered against the respiratory syncytial virus (RSV) met its efficacy and safety endpoints, notably reducing virus-related lower respiratory tract infections (LRTIs) after 150 days.
Merck - which says it is encouraged by these results - states that it plans to present detailed data from the study at a forthcoming scientific congress, before filing registration applications with health authorities worldwide.
Copyright (c) 2024 CercleFinance.com. All rights reserved.